Review

Introduction to Biofilms in Family Medicine

Authors: William Johnjulio, MD, LaDonna H. Fuge, MD, Manjusha Kad, MD, Christopher Post, MD

Abstract

Abstract: The management of common infections in family medicine can be complicated by poor treatment response or infection recurrence. Bacteria can grow as free-floating, planktonic bacteria or complex communities called biofilms. Biofilms promote bacterial growth and diversity and offer unique environments, including both aerobic and anaerobic layers, to bacteria. Although most treatments are tested against planktonic bacteria grown in the laboratory, infections in patients usually are the more complex and difficult to treat biofilms. Biofilms offer bacteria enhanced resistance to antimicrobial therapies that may otherwise be effective against planktonic bacteria. In many cases, difficulty treating recurring and recalcitrant infections can be explained by the important role of biofilms.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Chen L, Wen YM. The role of bacterial biofilm in persistent infections and control strategies. Int J Oral Sci 2011; 3: 66–73.
 
2. Lazăr V, Chififiuc MC. Architecture and physiology of microbial biofilms. Roum Arch Microbiol Immunol 2010; 69: 95–107.
 
3. Fey PD. Modality of bacterial growth presents unique targets: how do we treat biofilm-mediated infections? Curr Opin Microbiol 2010; 13: 610–615.
 
4. Weigel LM, Donlan RM, Shin DH, et al. High-level vancomycin-resistant Staphylococcus aureusisolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007; 51: 231–238.
 
5. Ceri H, Olson ME, Stremick C, et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771–1776.
 
6. Keays T, Ferris W, Vandemheen KL, et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009; 8: 122–127.
 
7. Pearlman AN, Conley DB. Review of current guidelines related to the diagnosis and treatment of rhinosinusitis. Curr Opin Otorhinolaryngol Head Neck Surg 2008; 16: 226–230.
 
8. Smith WM, Davidson TM, Murphy C. Regional variations in chronic rhinosinusitis, 2003-2006. Otorhinolaryngol Head Neck Surg 2009; 141: 347–352.
 
9. Slavin RG. The upper and lower airways: the epidemiological and pathophysiological connection. Allergy Asthma Proc 2008; 29: 553–556.
 
10. Dixon AE. Rhinosinusitis and asthma: the missing link. Curr Opin Pulm Med 2009; 15: 19–24.
 
11. Suh JD, Cohen NA, Palmer JN. Biofilms in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2010; 18: 27–31.
 
12. Prince AA, Steiger JD, Khalid AN, et al. Prevalence of biofilm-forming bacteria in chronic rhinosinusitis. Am J Rhinol 2008; 22: 239–245.
 
13. Foreman A, Psaltis AJ, Tan LW, et al. Characterization of bacterial and fungal biofilms in chronic rhinosinusitis. Am J Rhinol Allergy 2009; 23: 556–561.
 
14. Foreman A, Singhal D, Psaltis AJ, et al. Targeted imaging modality selection for bacterial biofilms in chronic rhinosinusitis. Laryngoscope 2010; 120: 427–431.
 
15. Goldstein-Daruech N, Cope EK, Zhao KQ, et al. Tobacco smoke mediated induction of sinonasal microbial biofilms. PLoS One 2011; 6: e15700.
 
16. Leibovitz E. Complicated otitis media and its implications. Vaccine 2008; 26 (7 suppl): G16–G19.
 
17. Armbruster CE, Swords EW. Interspecies bacterial communication as a target for therapy in otitis media. Expert Rev Anti Infect Ther 2010; 8: 1067–1070.
 
18. Leibovitz E, Greenberg D, Piglansky L, et al. Recurrent acute otitis media occurring within one month from completion of antibiotic therapy: relationship to the original pathogen. Pediatr Infect Dis J 2003; 22: 209–216.
 
19. Nistico L, Kreft R, Gieseke A, et al. An adenoid reservoir for pathogenic biofilm bacteria. J Clin Microbiol 2011; 49: 1411–1420.
 
20. Hoa M, Syamal M, Schaeffer MA, et al. Biofilms and chronic otitis media: an initial exploration into the role of biofilms in the pathogenesis of chronic otitis media. Am J Otolaryngol 2010; 31: 241–245.
 
21. Zuliani G, Carlisle M, Duberstein A, et al. Biofilm density in the pediatric nasopharynx: recurrent acute otitis media versus obstructive sleep apnea. Ann Otol Rhinol Laryngol 2009; 118: 519–524.
 
22. Moriyama S, Hotomi M, Shimada J, et al. Formation of biofilm by Haemophilus influenzae isolated from pediatric intractable otitis media. Auris Nasus Larynx 2009; 36: 525–531.
 
23. Campbell MK, Silver RW, Hoch JS, et al. Re-utilization outcomes and costs of minor acute illness treated at family physician offices, walk-in clinics, and emergency departments. Can Fam Physician 2005; 51: 82–83.
 
24. Stickler DJ. Bacterial biofilms in patients with indwelling urinary catheters. Nat Clin Pract Urol 2008; 5: 598–608.
 
25. Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control 2004; 32: 177–183.
 
26. Falagas ME, Kapaskelis AM, Kouranos VD, et al. Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence. Drugs 2009; 69: 1351–1361.
 
27. Holá V, Ruzicka F, Horka M. Microbial diversity in biofilm infections of the urinary tract with the use of sonication techniques. FEMS Immunol Med Microbiol 2010; 59: 525–528.
 
28. Macleod SM, Stickler DJ. Species interactions in mixed-community crystalline biofilms on urinary catheters. J Med Microbiol 2007; 56: 1549–1557.
 
29. Jones BV, Mahenthiralingam E, Sabbuba NA, et al. Role of swarming in the formation of crystalline Proteus mirabilis biofilms on urinary catheters. J Med Microbiol 2005; 54: 807–813.
 
30. Ndip A, Jude EB. Emerging evidence for neuroischemic diabetic foot ulcers: model of care and how to adapt practice. Int J Low Extrem Wounds 2009; 8: 82–94.
 
31. James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen 2008; 16: 37–44.
 
32. Fisher TK, Wolcott R, Wolk DM, et al. Diabetic foot infections: a need for innovative assessments. Int J Low Extrem Wounds 2010; 9: 31–36.
 
33. Dowd SE, Sun Y, Secor PR, et al. Survey of bacterial diversity in chronic wounds using Pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol 2008; 8: 43.
 
34. Dowd SE, Wolcott RD, Sun Y, et al. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One 2008; 3: e3326.
 
35. Ha KR, Psaltis AJ, Butcher AR, et al. In vitro activity of mupirocin on clinical isolates ofStaphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope 2008; 118: 535–540.
 
36. Uren B, Psaltis A, Wormald PJ. Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. Laryngoscope 2008; 118: 1677–1680.
 
37. Zanin JC, Gonçalves RB, Junior AB, et al. Susceptibility of Streptococcus mutans biofilms to photodynamic therapy: an in vitro study. J Antimicrob Chemother 2005; 56: 324–330.
 
38. Bevilacqua IM, Nicolau RA, Khouri S, et al. The impact of photodynamic therapy on the viability of Streptococcus mutans in a planktonic culture. Photomed Laser Surg 2007; 25: 513–518.
 
39. Di Poto A, Sbarra MS, Provenza G, et al. The effect of photodynamic treatment combined with antibiotic action or host defense mechanisms on Staphylococcus aureus biofilms. Biomaterials 2009; 30: 158–166.
 
40. Fontana CR, Abernathy AD, Som S, et al. The antibacterial effect of photodynamic therapy in dental plaque-derived biofilms. J Periodontal Res 2009; 44: 751–759.
 
41. Vattem DA, Mihalik K, Crixell SH, et al. Dietary phytochemicals as quorum sensing inhibitors. Fitoerapia 2007; 78: 302–310.
 
42. Tateda K, Ishii Y, Kimura S, et al. Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an Oriental mystery? J Infect Chemother 2007; 13: 357–367.
 
43. Skindersoe M, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing inPseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 3648–3663.